Stockscreener 앱 받기
3.94
2.72%
-0.11
Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스
Jobs Data: Is Atossa Therapeutics Incs growth already priced inJuly 2025 Price Swings & Stepwise Swing Trade Plans - baoquankhu1.vn
Atossa Therapeutics issues letter to shareholders highlighting 2025 accomplishments and 2026 outlook - marketscreener.com
Atossa Therapeutics Issues 2026 Outlook and Strategic Update - TipRanks
Atossa Therapeutics Issues Letter To Shareholders Highlighting 2025 Accomplishments And 2026 Outlook - TradingView
Atossa Therapeutics Issues 2026 Shareholder Letter Highlighting Key Developments - TradingView
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook - PR Newswire
Atossa Therapeutics launches research program for oral therapy in DMD - Traders Union
We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully - Yahoo Finance
Market Outlook: Is Atossa Therapeutics Inc part of any ETFWeekly Trading Summary & Weekly Momentum Picks - baoquankhu1.vn
Mammoth Energy sets March 6 call to review full-year 2025 results - Stock Titan
Atossa Therapeutics Maintains Strong Market Position for (Z)-End - GuruFocus
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program - Sahm
ATOS stock tumbles 32% — here’s what retail investors think of the reverse stock split - MSN
Atossa Genetics (NASDAQ:ATOS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
ATOS Stock Tumbles 32% — Here’s What Retail Investors Think Of The Reverse Stock Split - Asianet Newsable
Atossa Genetics (NASDAQ:ATOS) Sets New 1-Year LowWhat's Next? - MarketBeat
Atossa Therapeutics (ATOS) enters reverse-split Monday as Nasdaq compliance clock tightens - TechStock²
Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 56.4% in January - MarketBeat
Aug PreEarnings: How volatile is SKYQ stockWeekly Market Summary & Weekly Market Pulse Updates - baoquankhu1.vn
Atossa Genetics (NASDAQ:ATOS) Shares Set to Reverse Split on Monday, February 2nd - MarketBeat
Can Atossa Therapeutics Inc. lead its sector in growthGap Up & Verified Swing Trading Watchlist - mfd.ru
Atossa Therapeutics, Inc.'s (NASDAQ:ATOS) Profit Outlook - simplywall.st
Risk Hedge: Can Adagene Inc. Depositary Receipt stock outperform in a bear market2025 Sector Review & Long-Term Safe Investment Plans - baoquankhu1.vn
Financial Review: Atossa Genetics (NASDAQ:ATOS) versus ADM Tronics Unlimited (OTCMKTS:ADMT) - Defense World
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 - PR Newswire
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 (2026-01-21) - Seeking Alpha
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy - BioSpace
Big Picture: Is Atossa Therapeutics Inc part of any ETF2025 Fundamental Recap & Reliable Price Breakout Signals - baoquankhu1.vn
Atossa Therapeutics (ATOS) Gains as FDA Grants Orphan Drug Statu - GuruFocus
ATOS Receives FDA Orphan Drug Designation for Duchenne Treatment - GuruFocus
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z) - GuruFocus
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy - Intellectia AI
Experimental DMD treatment from Atossa earns rare FDA orphan status - Stock Titan
Atossa Therapeutics (ATOS) Receives Orphan Drug Designation, Shares Rise 10% - Intellectia AI
Atossa Therapeutics (ATOS) Receives FDA Orphan Drug Designation, Shares Rise 13% - Intellectia AI
Why Did ATOS Stock Jump 10% In Pre-Market Today? - Asianet Newsable
FDA Grants Orphan Drug Status to Atossa Therapeutics' (ATOS) Z-E - GuruFocus
What Wall Street predicts for Atossa Therapeutics Inc stock priceAnalyst Upgrade & AI Forecast Swing Trade Picks - Bộ Nội Vụ
Atossa Therapeutics targets breast cancer care breakthroughs - Traders Union
Atossa Therapeutics outlines strategy for lead (Z)-Endoxifen program - The Globe and Mail
Will Atossa Therapeutics Inc. (YAG2) stock beat revenue estimatesWalking Comfort Picks & HOKA buying tips before checkout - ulpravda.ru
Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200 Day Moving Average – Here’s Why - Defense World
Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200 Day Moving AverageHere's Why - MarketBeat
Is Atossa Therapeutics Inc. stock in correction or buying zoneJuly 2025 Outlook & Community Verified Watchlist Alerts - Улправда
Will Atossa Therapeutics Inc. stock benefit from AI adoptionQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - Улправда
Will Atossa Therapeutics Inc. stock outperform growth indexesWeekly Stock Analysis & Verified Momentum Watchlists - Улправда
What margin trends mean for Atossa Therapeutics Inc. stockPortfolio Gains Summary & Safe Swing Trade Setups - Улправда
Is Atossa Therapeutics Inc. (YAG2) stock supported by strong fundamentalsMarket Sentiment Report & Real-Time Volume Spike Alerts - Улправда
1.24%
0.19%
자본화:
|
볼륨(24시간):